.. Chiasma, Roche enter contract to develop and commercialize Octreolin Roche and Chiasma Inc., a privately held biopharma company, announced today they have entered into an contract to build up and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral type of the peptide octreotide, a somatostatin analog that is available only by injection commercially. Genentech shall market the product in the usa after US FDA acceptance. Chiasma will continue development through completion of the pivotal phase 3 scientific trial for acromegaly.This brand-new partnership provides 12,000 MEDENT physician users with the ability to connect their Quinton and Burdick ECG, cardiac stress check, and Holter systems with the MEDENT EMR/EHR systems. Cardiac Science, with an installed client base greater than 65,000 diagnostic monitoring devices, can connect its gadgets with MEDENT systems for a clean transfer of test outcomes. Related StoriesNovel culturally-educated treatment benefits caregivers of people with schizophreniaBoston Children's and Rock Health synergy to accelerate development of pediatric health technologiesEstradiol fluctuation might enhance emotional sensitivity to psychosocial stress during menopausal transition’Our customers wish Cardiac Science’s market-leading cardiac monitoring gadgets to connect with leading EMRs and EHRs,’ said Dave Marver, Cardiac Technology president and chief executive officer.